- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07939334
Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy Adults
The Acute Effects of Sideritis Scardica (Greek Mountain Tea) on Cognitive Performance and Cerebral Blood Flow in Healthy Adults
The goal of this clinical trial is to learn how a study product affects cognitive performance and cerebral responses in adults. The study will also collect information about the safety of the study product. Participants will attend a screening visit followed by two study visits. During the study visits, participants will complete computerized cognitive assessments before and after consuming the study product and will wear a NIRS headband to record cerebral responses. Researchers will also monitor participants for adverse events and changes in medications or supplements during the study.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This clinical trial investigates the acute effects of a Sideritis scardica study product on cognitive performance and cerebral responses during cognitive tasks in adults.
Participants will undergo computerized cognitive assessments together with near infrared spectroscopy (NIRS) recording before and after consumption of the study product. Cognitive testing includes choice reaction time (CRT) and rapid visual information processing (RVIP) tasks. NIRS recording is performed during the assessment periods to characterize cerebral responses associated with cognitive task performance.
Following screening, eligible participants will attend two intervention visits. The first intervention visit represents Day 1, and the second is scheduled approximately 8 days later. At each visit, cognitive and NIRS assessments are performed before study product consumption and are repeated after consumption. Standardized resting NIRS recording periods are incorporated into the assessment sequence.
Adverse events and relevant changes in medical conditions, medications, and supplements will be monitored throughout the study.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Cynthia G. Suarez, PhD.
- Numero di telefono: +4916098144462
- Email: cynthia.suarez-rizzo@martin-bauer.com
Luoghi di studio
-
-
RLP
-
Andernach, RLP, Germania, 56626
- Finzelberg
-
-
-
-
-
Cork, Irlanda
- Atlantia Clinical Trials
-
Contatto:
- Scientific Director
- Numero di telefono: 7442 +353 (0) 021-430
- Email: krea@atlantiatrials.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Be able to give written informed consent.
- Be between 18-70 years of age.
- BMI between 18.5 and 30.0 kg/m2
- Willing to refrain from consuming alcohol for 24 h, non-habitual stimulants for 18 h prior to Visit 2 (Day 1) and Visit 3 (Day 8).
- Willing and able to comply with all study procedures and consume the study product as instructed at each study visit.
Exclusion Criteria:
-
Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
-
Participants currently of biological childbearing potential but not using a continuous effective method of contraception as determined by the investigator.
-
Has a history of drug and/or alcohol abuse (within 12 months prior to visit 1)
-
Participants that are habitual smokers or vapers
-
High caffeine intake, >400mg/day (approximately equivalent to ≥4 cups of coffee per day
-
Has food allergies, or other issues with foods, that would preclude intake of the study products.
-
Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:
- Uncontrolled hypertension
- Clinically significant neurological or mental health conditions (history of stroke/TIA, epilepsy, traumatic brain injury with loss of consciousness, diagnosed ADHD, major depressive disorder within last 6 months)
- Diagnosed cognitive impairment
- Type I or II diabetes
- Clinically significant cardiovascular, liver and renal disease
- Diagnosed gastrointestinal conditions (IBD, coeliac disease)
-
Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. Prohibited medications include:
a) Prescription medications such a hypnotic, BDZs, antidepressants, antipsychotics, stimulants, beta-blockers, vasodilators, nootropics, and any psychoactive drugs (in the past 2 weeks prior to visit 1)
-
Current or recent (in the past 2 weeks) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator, including:
- Ginseng, ginkgo biloba, Luteolin, Apigenin supplements
- Products containing Sideritis, Sage, Thymus and Oregano
-
Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
-
Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
Placebo supplement containing carrier material only |
Placebo supplement containing carrier material only |
|
Sperimentale: Siderits
Sideritis supplement administered at an estimated daily dose |
Sideritis scardica preparation (Greek Mountain Tea) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Difference between the Sideritis scardica (Greek Mountain Tea) extract, and placebo in the change from pre-dose assessment to the post-dose assessment period in Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)
Lasso di tempo: Baseline, day 1, day 7
|
Evaluate the acute effects of Greek Mountain Tea extract, compared with placebo on Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1) |
Baseline, day 1, day 7
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cognitive performance during the test called Choice Reaction Time (CRT)
Lasso di tempo: Baseline, day 1, day 7
|
Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of Choice Reaction Time (CRT) with the measurement of following parameters: Choice Reaction Time accuracy, Choice Reaction Time (overall reaction time), Choice Reaction Time (correct response reaction time), Choice Reaction Time Number of Errors (%) |
Baseline, day 1, day 7
|
|
Cognitive Performance: Rapid Visual Information Processing (RVIP)
Lasso di tempo: Baseline, day 1, day 7
|
Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of RVIP response time, RVIP false alarms, RVIP Number of Correct Detections (Hits) |
Baseline, day 1, day 7
|
|
Cerebral total haemoglobin approximately 150 to 240 minutes after administration
Lasso di tempo: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation as assessed by near-infrared spectroscopy (NIRS) analysis to determine total haemoglobin. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral oxygenation
Lasso di tempo: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis, concurrent changes in tissue saturation index to determine total oxygen saturation. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral oxygenated haemoglobin (HbO2) approximately 150 to 240 minutes after administration
Lasso di tempo: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determine oxygenated haemoglobin (HbO2) levels. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral deoxygenated hemoglobin (HHb) approximately 150 to 240 minutes after administration
Lasso di tempo: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determinedeoxygenated hemoglobin (HHb) levels. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- Heiner F, Feistel B, Wink M. Sideritis scardica extracts inhibit aggregation and toxicity of amyloid-beta in Caenorhabditis elegans used as a model for Alzheimer's disease. PeerJ. 2018 Apr 30;6:e4683. doi: 10.7717/peerj.4683. eCollection 2018.
- Wightman EL, Jackson PA, Khan J, Forster J, Heiner F, Feistel B, Suarez CG, Pischel I, Kennedy DO. The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis scardica (Greek Mountain Tea) Extract: A Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans. Nutrients. 2018 Jul 24;10(8):955. doi: 10.3390/nu10080955.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- FB_AF216
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The IPD dataset will include de-identified participant-level demographic and baseline characteristics, treatment allocation, and individual results for the primary and secondary outcome measures included in the published analyses. Derived variables necessary to reproduce the reported statistical analyses may also be included. Direct identifiers and other information that could reasonably permit participant identification will not be shared.
Periodo di condivisione IPD
Start date: Following completion of the study and publication of the primary study results.
End date: Available thereafter upon reasonable request, subject to applicable data-retention requirements and sponsor policies.
Criteri di accesso alla condivisione IPD
Qualified researchers may request access to de-identified IPD underlying the reported results and relevant supporting documents. Requests must include a scientifically sound proposal and will be reviewed by the study sponsor/data custodian. Approved applicants will receive only the data necessary for the approved purpose through an appropriate secure data-sharing mechanism and, where applicable, under a data-use agreement. No directly identifiable participant information will be shared.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .